Grace Therapeutics grants PFO 33,660 stock options

Grace Therapeutics, Inc. (GRCE) reported that its Principal Financial Officer, Robert J. DelAversano, received a grant of stock options covering 33,660 shares of common stock on 2026-08-28.

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) reported that its Principal Financial Officer, Robert J. DelAversano, received a grant of stock options covering 33,660 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27.

These options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting equally over the following 11 quarters, subject to his continuous service. Following this award, he holds 33,660 derivative securities of this type directly.

Insider Trade Summary

Grant/Award: 33,660 shares

Grant/Award 1 txn

Insider DelAversano Robert J

Role Principal Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	33,660	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 33,660 contracts (Direct)

Footnotes (1)

1. F1. These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.

Key Figures

Stock options granted: 33,660 options Exercise price: $2.12 per share Underlying common shares: 33,660 shares +4 more

7 metrics

Stock options granted 33,660 options Grant to Principal Financial Officer on 2026-08-28

Exercise price $2.12 per share Exercise/conversion price of granted stock options

Underlying common shares 33,660 shares Common Stock underlying the stock option grant

Post-transaction derivative holdings 33,660 options Total stock options of this type held after the grant

Option expiration date 2036-08-27 Expiration of the granted stock options

Immediate vesting portion 1/12 of grant Vests immediately on the grant date, subject to service

Remaining vesting tranches 11 quarters Remaining 11/12 vest equally over the following 11 quarters

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion or exercise price of $2.1200 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"These options vest quarterly in substantially equal installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What transaction did GRCE report for Robert J. DelAversano on this Form 4?

Grace Therapeutics, Inc. reported that Principal Financial Officer Robert J. DelAversano received a grant of 33,660 stock options on 2026-08-28, giving him the right to buy GRCE common stock, with vesting over three years.

What is the exercise price of the new stock options granted by GRCE to the PFO?

The stock options granted to Robert J. DelAversano have an exercise price of $2.12 per share. This is the price at which he may purchase Grace Therapeutics, Inc. common stock upon exercising the options before expiration.

How many Grace Therapeutics (GRCE) options does the PFO hold after this grant?

After this grant, Principal Financial Officer Robert J. DelAversano holds 33,660 stock options of this type directly, each relating to one share of Grace Therapeutics, Inc. common stock.

What is the vesting schedule for the GRCE stock options granted to the PFO?

The options vest quarterly over three years. 1/12 of the grant vests immediately on the grant date, and the remaining 11/12 vest equally over the next 11 quarters, conditioned on his continuous service at each vesting date.

When do the newly granted GRCE stock options expire?

The stock options granted to Robert J. DelAversano expire on 2036-08-27. He may exercise vested options at the $2.12 per share exercise price any time before this expiration date, subject to plan terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:08 PM Accepted by SEC EDGAR 09/01/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DelAversano Robert J

(Last) (First) (Middle)

C/O GRACE THERAPEUTICS, INC.

103 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.12	08/28/2026		A		33,660		(1)	08/27/2036	Common Stock	33,660	$0	33,660	D

Explanation of Responses:

1. These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.

	/s/ Robert DelAversano	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)